Perceptive Advisors LLC Acquires Shares of 6,314,452 X4 Pharmaceuticals, Inc. $XFOR

Perceptive Advisors LLC acquired a new stake in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 6,314,452 shares of the company’s stock, valued at approximately $25,258,000. Perceptive Advisors LLC owned 7.22% of X4 Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of XFOR. Empery Asset Management LP acquired a new position in X4 Pharmaceuticals in the fourth quarter valued at $35,804,000. Bain Capital Life Sciences Investors LLC increased its stake in X4 Pharmaceuticals by 227.0% in the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 7,967,454 shares of the company’s stock valued at $31,870,000 after purchasing an additional 5,530,866 shares during the period. Kalehua Capital Management LLC acquired a new position in X4 Pharmaceuticals in the fourth quarter valued at $14,891,000. Braidwell LP acquired a new position in X4 Pharmaceuticals in the fourth quarter valued at $13,476,000. Finally, Nantahala Capital Management LLC acquired a new position in X4 Pharmaceuticals in the third quarter valued at $7,621,000. 72.03% of the stock is currently owned by institutional investors and hedge funds.

X4 Pharmaceuticals Stock Up 0.2%

Shares of NASDAQ:XFOR opened at $4.05 on Thursday. The company has a market cap of $382.00 million, a price-to-earnings ratio of -0.89 and a beta of 0.34. The firm’s 50-day simple moving average is $4.08 and its 200-day simple moving average is $3.89. The company has a quick ratio of 9.98, a current ratio of 10.18 and a debt-to-equity ratio of 0.45. X4 Pharmaceuticals, Inc. has a fifty-two week low of $1.35 and a fifty-two week high of $4.83.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.04. The business had revenue of $2.71 million for the quarter, compared to the consensus estimate of $3.20 million. X4 Pharmaceuticals had a negative net margin of 1,106.30% and a negative return on equity of 94.90%. As a group, equities research analysts predict that X4 Pharmaceuticals, Inc. will post -0.77 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Leerink Partners assumed coverage on shares of X4 Pharmaceuticals in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 price objective on the stock. Weiss Ratings lowered shares of X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 4th. Guggenheim started coverage on shares of X4 Pharmaceuticals in a report on Monday, March 9th. They issued a “buy” rating and a $12.00 target price on the stock. Finally, Wall Street Zen raised shares of X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, X4 Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.38.

X4 Pharmaceuticals Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.